ESS2 tends to be highly expressed in prostate cancer patients, and expression levels of some ESS2 target genes, such as LIF, WNT5A, and TGFB1, were significantly correlated with ESS2 levels in prostate cancer patients. This evidence concerns the gene WNT5A and prostate cancer.